Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
56.93
Dollar change
+1.03
Percentage change
1.84
%
Index- P/E- EPS (ttm)-2.95 Insider Own0.98% Shs Outstand181.91M Perf Week-5.16%
Market Cap10.36B Forward P/E- EPS next Y-0.20 Insider Trans0.00% Shs Float180.13M Perf Month-18.66%
Income-518.25M PEG- EPS next Q-0.18 Inst Own46.96% Short Float5.83% Perf Quarter-3.72%
Sales285.14M P/S36.32 EPS this Y23.78% Inst Trans19.05% Short Ratio10.77 Perf Half Y-11.54%
Book/sh6.88 P/B8.28 EPS next Y82.22% ROA- Short Interest10.51M Perf Year21.21%
Cash/sh7.20 P/C7.91 EPS next 5Y- ROE- 52W Range44.52 - 77.32 Perf YTD-5.38%
Dividend Est.- P/FCF- EPS past 5Y-168.48% ROI-32.87% 52W High-26.37% Beta0.02
Dividend TTM- Quick Ratio6.83 Sales past 5Y50.60% Gross Margin49.42% 52W Low27.88% ATR (14)2.99
Dividend Ex-Date- Current Ratio6.92 EPS Y/Y TTM-14.41% Oper. Margin-155.09% RSI (14)37.54 Volatility4.74% 4.99%
Employees1826 Debt/Eq0.26 Sales Y/Y TTM- Profit Margin-181.75% Recom1.42 Target Price86.42
Option/ShortYes / Yes LT Debt/Eq0.26 EPS Q/Q-52.63% Payout- Rel Volume0.64 Prev Close55.90
Sales Surprise-15.53% EPS Surprise-12.49% Sales Q/Q190.43% EarningsMar 11 BMO Avg Volume975.67K Price56.93
SMA20-9.84% SMA50-6.36% SMA200-12.41% Trades Volume628,703 Change1.84%
Date Action Analyst Rating Change Price Target Change
Mar-13-24Initiated Raymond James Outperform $86
Dec-19-23Initiated Scotiabank Sector Perform
Nov-06-23Initiated Goldman Buy $90.09
May-25-23Initiated William Blair Mkt Perform $64
May-22-23Initiated Daiwa Securities Buy
Mar-29-23Initiated H.C. Wainwright Buy $66
Mar-24-23Initiated RBC Capital Mkts Outperform $73
Dec-06-22Initiated UBS Buy $66
Nov-02-22Initiated Evercore ISI Outperform
Nov-01-22Initiated Cowen Outperform
Mar-19-24 08:30AM
Mar-17-24 08:50AM
Mar-15-24 03:15PM
Mar-12-24 08:20AM
Mar-11-24 07:00AM
07:15AM Loading…
Feb-23-24 07:15AM
Feb-13-24 08:00AM
Feb-07-24 02:41AM
Jan-22-24 08:34PM
08:11PM
08:05AM
Jan-03-24 08:30AM
Jan-02-24 10:29AM
08:30AM
Dec-26-23 06:56PM
11:40AM Loading…
Dec-19-23 11:40AM
Dec-11-23 07:30PM
Nov-28-23 02:51PM
Nov-24-23 04:02PM
Nov-20-23 11:09PM
06:00AM
Nov-16-23 05:50AM
Nov-14-23 10:47AM
Nov-13-23 08:30AM
07:00AM
Nov-07-23 08:30AM
Nov-02-23 09:17AM
Oct-30-23 10:39AM
Oct-20-23 05:10AM
Oct-03-23 05:52AM
08:00AM Loading…
Sep-21-23 08:00AM
Aug-16-23 02:40AM
Aug-15-23 06:00AM
Aug-14-23 08:36AM
07:15AM
Aug-10-23 08:14AM
Aug-07-23 06:57PM
Aug-03-23 08:30AM
Aug-02-23 09:56AM
Jul-25-23 02:45AM
Jun-29-23 02:00AM
Jun-07-23 08:35AM
Jun-06-23 04:30PM
Jun-05-23 11:04AM
Jun-02-23 04:01PM
May-25-23 08:30AM
May-23-23 03:14PM
May-18-23 08:30AM
May-16-23 08:35AM
May-11-23 04:01PM
May-08-23 08:30AM
May-03-23 10:25PM
May-01-23 09:25AM
Apr-21-23 04:03PM
Apr-20-23 11:04AM
01:52AM
Apr-19-23 07:22PM
04:06PM
01:04PM
12:40PM
10:22AM
Apr-11-23 08:30AM
Apr-03-23 04:01PM
Apr-02-23 09:49AM
Apr-01-23 09:45AM
09:00AM
Mar-30-23 04:01PM
Mar-29-23 08:54PM
04:40PM
Mar-24-23 02:47AM
Feb-25-23 11:38AM
Feb-24-23 08:30AM
Feb-21-23 08:30AM
Jan-27-23 09:54AM
08:32AM
Jan-03-23 04:01PM
Jan-02-23 04:45AM
Dec-26-22 08:37PM
Dec-14-22 05:37AM
Nov-21-22 08:30AM
Nov-04-22 05:00PM
Nov-03-22 04:01PM
Oct-19-22 11:51AM
Oct-18-22 05:14PM
Oct-10-22 01:38PM
Sep-27-22 09:09AM
Sep-15-22 08:30AM
Sep-01-22 02:07PM
Aug-19-22 04:01PM
Aug-16-22 10:13AM
Aug-05-22 08:30AM
Aug-04-22 04:01PM
Jul-31-22 06:23AM
Jul-28-22 08:30AM
Jul-27-22 05:58PM
Jul-26-22 08:00PM
Jul-25-22 04:01PM
Jul-20-22 10:11AM
Jun-17-22 02:24PM
Jun-10-22 05:00PM
Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.